ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022
ViewRay, Inc. (Nasdaq: VRAY) will host a Virtual Clinical Data Event on March 16, 2022, at 4:00 pm ET. The event will highlight clinical trials, specifically the MIRAGE and SCIMITAR studies in prostate cancer radiation therapy, featuring Dr. Amar Kishan from UCLA and Dr. Himanshu Nagar from Weill Cornell Medicine. Registration is available on their website, and a replay will be accessible post-event. ViewRay focuses on developing the MRIdian® MR-Guided Radiation Therapy System, designed to enhance radiation oncology.
- Hosting a Virtual Clinical Data Event to showcase clinical trials, which can enhance investor confidence.
- Engagement of notable experts in radiation therapy, potentially improving credibility and attracting attention.
- None.
CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday, March 16, 2022. The event will begin at 4:00 pm ET.
The Virtual Clinical Data Event will be hosted by the ViewRay leadership team and will feature the clinical work of Amar Kishan, M.D., Associate Professor and Chief of the Genitourinary Oncology Service at UCLA. The event will feature a fireside chat between Dr. Kishan and Dr. Himanshu Nagar, M.D., radiation oncologist and Assistant Professor, Weill Cornell Medicine, New York-Presbyterian, regarding the MIRAGE and SCIMITAR clinical trials and the future of prostate cancer radiation therapy.
To participate in the event, guests must register either on the company's website or at https://viewray.zoom.us/webinar/register/WN_oqm7dpQNTYm8tduBCKwqKw. A replay of the event will be available on the company's website following the event.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Financial Disclosure: Drs. Kishan and Nagar, respectively, have received: (i) research support; and (ii) consulting fees (not related to these trials), from ViewRay, Inc.
View original content:https://www.prnewswire.com/news-releases/viewray-to-host-a-virtual-clinical-data-event-for-investors-and-analysts-on-march-16-2022-301500295.html
SOURCE ViewRay, Inc.
FAQ
What is the purpose of ViewRay's Virtual Clinical Data Event on March 16, 2022?
Who will be speaking at the ViewRay's Virtual Clinical Data Event?
How can investors participate in ViewRay's upcoming clinical event?
What key topics will be discussed at the Virtual Clinical Data Event?
